Skip to main content
OpenTrials

Clinical trial condition

Skin Neoplasms

Explore clinical trials studying Skin Neoplasms. Study availability and eligibility vary by location and protocol.

2,110 public trials 360 recruiting studies
Refine in advanced search Browse all conditions

Skin Neoplasms trial results

Active, Not Recruiting

MAGE-A4ᶜ¹º³²T for Multi-Tumor

NCT03132922

Conditions
Adenocarcinoma, Adnexal Diseases, Bronchial Neoplasms, +67 more
Locations
  • University of Miami Miami, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • Washington University St Louis, Missouri, United States
View Trial Details
Active, Not Recruiting

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

NCT05625399

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
Locations
  • Local Institution - 0125 Phoenix, Arizona, United States
  • Local Institution - 0189 Springdale, Arkansas, United States
  • Local Institution - 0098 Los Angeles, California, United States
  • Local Institution - 0093 Orange, California, United States
View all 149 locations
View Trial Details
Active, Not Recruiting

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT04013685

Conditions
Acute Leukemia, Acute Lymphoid Leukemia, Acute Myeloid Leukemia, +31 more
Locations
  • City of Hope Duarte, California, United States
  • Ronald Reagan UCLA Medical Center Los Angeles, California, United States
  • UC Davis Sacramento, California, United States
  • Stanford Health Care Stanford, California, United States
View all 21 locations
View Trial Details
Active, Not Recruiting

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

NCT05912244

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
Locations
  • Hartford Healthcare Alliance (Data Collection Only) Hartford, Connecticut, United States
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
View Trial Details
Active, Not Recruiting

Dinaciclib in Treating Patients With Stage IV Melanoma

NCT00937937

Conditions
Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma, Lentigo Maligna Melanoma, +16 more
Locations
  • Providence Hospital Mobile, Alabama, United States
  • Mercy Hospital Fort Smith Fort Smith, Arkansas, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Highlands Oncology Group - Rogers Rogers, Arkansas, United States
View all 190 locations
View Trial Details
Active, Not Recruiting

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NCT06131398

Conditions
Advanced Solid Tumors, Bronchial Neoplasms, Carcinoma, Bronchogenic, +29 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Alliance for Multispecialty Research - Kansas City Merriam, Kansas, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Washington University St Louis, Missouri, United States
View all 25 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04514484

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Differentiated Thyroid Gland Carcinoma, +141 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Adnexal Diseases, +91 more
Locations
  • Dignity Health St Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • Mayo Clinic Phoenix, Arizona, United States
  • City of Hope Cancer Center Duarte, California, United States
  • City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services Duarte, California, United States
View all 130 locations
View Trial Details

Related conditions